| A gain-of-function mutation of JAK2 in myeloproliferative disorders R Kralovics, F Passamonti, AS Buser, SS Teo, R Tiedt, JR Passweg, ... New England Journal of Medicine 352 (17), 1779-1790, 2005 | 4758 | 2005 |
| Somatic mutations of calreticulin in myeloproliferative neoplasms T Klampfl, H Gisslinger, AS Harutyunyan, H Nivarthi, E Rumi, JD Milosevic, ... New England Journal of Medicine 369 (25), 2379-2390, 2013 | 2455 | 2013 |
| A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease A Zimprich, A Benet-Pagès, W Struhal, E Graf, SH Eck, MN Offman, ... The American Journal of Human Genetics 89 (1), 168-175, 2011 | 1093 | 2011 |
| JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes E Rumi, D Pietra, V Ferretti, T Klampfl, AS Harutyunyan, JD Milosevic, ... Blood, The Journal of the American Society of Hematology 123 (10), 1544-1551, 2014 | 775 | 2014 |
| Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms P Lundberg, A Karow, R Nienhold, R Looser, H Hao-Shen, I Nissen, ... Blood, The Journal of the American Society of Hematology 123 (14), 2220-2228, 2014 | 737 | 2014 |
| Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms W Vainchenker, R Kralovics Blood, The Journal of the American Society of Hematology 129 (6), 667-679, 2017 | 713 | 2017 |
| A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms D Olcaydu, A Harutyunyan, R Jäger, T Berg, B Gisslinger, I Pabinger, ... Nature genetics 41 (4), 450-454, 2009 | 435 | 2009 |
| Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera R Kralovics, Y Guan, JT Prchal Experimental hematology 30 (3), 229-236, 2002 | 428 | 2002 |
| Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders D Pietra, S Li, A Brisci, F Passamonti, E Rumi, A Theocharides, M Ferrari, ... Blood, The Journal of the American Society of Hematology 111 (3), 1686-1689, 2008 | 425 | 2008 |
| Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial H Gisslinger, M Gotic, J Holowiecki, M Penka, J Thiele, HM Kvasnicka, ... Blood, The Journal of the American Society of Hematology 121 (10), 1720-1728, 2013 | 419 | 2013 |
| Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants I Chachoua, C Pecquet, M El-Khoury, H Nivarthi, RI Albu, C Marty, ... Blood, The Journal of the American Society of Hematology 127 (10), 1325-1335, 2016 | 379 | 2016 |
| Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders R Kralovics, SS Teo, S Li, A Theocharides, AS Buser, A Tichelli, ... Blood 108 (4), 1377-1380, 2006 | 347 | 2006 |
| The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera E Lippert, M Boissinot, R Kralovics, F Girodon, I Dobo, V Praloran, ... Blood 108 (6), 1865-1867, 2006 | 335 | 2006 |
| Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line P Essletzbichler, T Konopka, F Santoro, D Chen, BV Gapp, R Kralovics, ... Genome research 24 (12), 2059-2065, 2014 | 331 | 2014 |
| Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms JD Milosevic Feenstra, H Nivarthi, H Gisslinger, E Leroy, E Rumi, ... Blood, The Journal of the American Society of Hematology 127 (3), 325-332, 2016 | 325 | 2016 |
| Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis C Marty, C Pecquet, H Nivarthi, M El-Khoury, I Chachoua, M Tulliez, ... Blood, The Journal of the American Society of Hematology 127 (10), 1317-1324, 2016 | 303 | 2016 |
| Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study H Gisslinger, C Klade, P Georgiev, D Krochmalczyk, ... The Lancet Haematology 7 (3), e196-e208, 2020 | 299 | 2020 |
| From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms M Cazzola, R Kralovics Blood, The Journal of the American Society of Hematology 123 (24), 3714-3719, 2014 | 266 | 2014 |
| Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 R Kralovics, SS Teo, AS Buser, M Brutsche, R Tiedt, A Tichelli, ... Blood 106 (10), 3374-3376, 2005 | 262 | 2005 |
| p53 lesions in leukemic transformation A Harutyunyan, T Klampfl, M Cazzola, R Kralovics New England Journal of Medicine 364 (5), 488-490, 2011 | 255 | 2011 |
Mario CazzolaProfessor of Hematology, University of PaviaVerified email at unipv.it
